Compare NOMD & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMD | CAPR |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2015 | 2011 |
| Metric | NOMD | CAPR |
|---|---|---|
| Price | $10.06 | $28.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $12.50 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 1.1M | 775.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.45 | $3.31 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.99 | $4.30 |
| 52 Week High | $18.33 | $40.37 |
| Indicator | NOMD | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 49.30 |
| Support Level | $9.52 | $25.76 |
| Resistance Level | $10.49 | $30.21 |
| Average True Range (ATR) | 0.24 | 1.28 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 31.95 | 56.05 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.